APPLICATION
ANDA207320
TYPE
ANDA
ORIGINAL APPROVAL
2022-07-12
LATEST ACTION
2022-07-12
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
REGADENOSONPrescription
REGADENOSON 0.4MG/5ML (0.08MG/ML) · SOLUTION · INTRAVENOUS
Approval history
2022-07-12UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.